International Assets Investment Management LLC Sells 227,537 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

International Assets Investment Management LLC reduced its stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 79.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 59,750 shares of the biotechnology company's stock after selling 227,537 shares during the period. International Assets Investment Management LLC owned approximately 0.10% of Aldeyra Therapeutics worth $312,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Barclays PLC raised its holdings in shares of Aldeyra Therapeutics by 280.1% during the 3rd quarter. Barclays PLC now owns 65,561 shares of the biotechnology company's stock valued at $353,000 after buying an additional 48,313 shares in the last quarter. State Street Corp grew its holdings in shares of Aldeyra Therapeutics by 1.7% during the 3rd quarter. State Street Corp now owns 973,908 shares of the biotechnology company's stock valued at $5,249,000 after purchasing an additional 16,188 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in Aldeyra Therapeutics by 163.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company's stock worth $2,571,000 after purchasing an additional 295,864 shares during the period. Paloma Partners Management Co bought a new stake in Aldeyra Therapeutics in the third quarter worth $62,000. Finally, PDT Partners LLC bought a new position in shares of Aldeyra Therapeutics during the third quarter valued at about $169,000. 59.71% of the stock is currently owned by hedge funds and other institutional investors.

Aldeyra Therapeutics Price Performance

ALDX stock traded down $0.02 during trading on Monday, hitting $4.92. 57,580 shares of the company traded hands, compared to its average volume of 352,714. The company has a 50-day moving average of $4.99 and a 200-day moving average of $4.93. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18. Aldeyra Therapeutics, Inc has a 1 year low of $2.71 and a 1 year high of $6.55.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.25). On average, analysts forecast that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current fiscal year.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.